Drugs / StromaForte
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06070532 | Jan 2025 → Jan 2026 overdue | — | Cellcolabs Clinical LTD. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06063590 | Jan 2024 → Aug 2025 | — | Cellcolabs Clinical SPV Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT06084988 | Nov 2023 → Oct 2024 | osteoarthritis, knee | Cellcolabs Clinical SPV Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT06074783 | Oct 2023 → Oct 2027 expected | musculoskeletal system disorder | Cellcolabs Clinical LTD. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06087848 | Oct 2023 → Oct 2029 expected | cardiovascular disorder | Cellcolabs Clinical LTD. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stromaforte | “Stromaforte cells which will be used in this study is developed within CELLCOLABS AB” NCT06084988 ↗ |
| Action | Restore | “MSCs can contribute to the reconstitution of damaged tissues, promoting structural and functional recovery.” NCT06074783 ↗ |
| Modality | Cell therapy | “allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC)” NCT06063590 ↗ |
| Route | Intravenous | “to be given via slow intravenous infusion” NCT06063590 ↗ |